Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (February 2022)
19 slides from Clearpoint Neuro's investor presentation, Feb 15, 2022
Slide 1: ClearPoint Neuro – February 2022
CLEARPOINT NEURO WHEN YOUR PATH | WE POINT THE WAY, Nasdaq: CLPT February 2022
Slide 2: Forward-looking statements
Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plan
Slide 3: ClearPoint Neuro: Two Opportunities, One Platform
Our Company ClearPoint Neuro: Two Opportunities, One Platform CLEARPOINT NEUR *« ACommon Installed Base Platform and Clinical Specialist Support team 35 Active Indications totaling more than 1 million patients diagnosed annually * A$12B+ Potential Total Addressable Market A Biologics & Drug Delivery
Slide 4: ClearPoint Neuro: A Proven Platform
Our Company ClearPoint Neuro: A Proven Platform Key Products: FDA. C€ Marked Platforms HEADQUARTERS MANUFACTURING EUROPEAN HEADQUARTERS Solana Beach, CA __ Irvine, CA London, UK 2021 REVENUE CASH a) (A) (A) $16.3m $54.1m U.S. PATENTS ISSUED 2021GROSS MARGIN Razor / Razorblade rs) (8) oy) model with
Slide 5: Limitations of Traditional Stereotactic Neurosurgery
Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible CLEARPOI
Slide 6: Our Platform — Procedure Overview
Our Platform — Procedure Overview The ClearPoint® Neuro Navigation System 388; CLEARPOINT © 2022 CLEARPOINT NEURO 6 38° NEURO
Slide 7: SmartFrame XG and SmartFrame Array
SmartFrame® XG SmartFrame Array® A eo (7 AY pep SmartFrame Array Tower with “virtual array” Software and next generation robotic system with increased automation and enabling software* ClearPoint plans to translate more than 10 years of experience and over 5,000 cases performed in the complex MRI su
Slide 8: The ClearPoint Maestro Brain Model
Our Platform The ClearPoint ‘Maestro’ Brain Model” Licensed and Jointly Developed with Philips 1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects 2. Fast and capable of peri-procedural imaging without CPU acceleration 3. This model is the basis fo
Slide 9: Broad and Growing User Base of Leading Institutions
Broad and Grow User Base of teeing eionicg ie san Francisco’ on & “University of Wisconsin _ Stanford University University of Michigan... € - * Stanford Children’s postal | University of Minnesota *- Children’s Mercy Hospital — _ UCSF Benioff Children’s _ §Cincinnati Children’s Hospital -.. CHOA Sc
Slide 10: Our MRI-guided therapy platform is currently being used
SIEMENS IMRIS es CLEARPOINT Our MRI-guided therapy platform is currently being used to... PTC) Medtronic = Abbott BlueRock B te pese oston, Scientific HENE qe uniQure MLSS charlesriver .. Approximately 40 total commercial and academic partners Medtronic MONTERIS MEDICAL CLEARPOINT NEURO *€xpected Fi
Slide 11: Growth in Case Volume and Revenue
2013 - 2022 Growth in Case Volume and Revenue 2013 2014 2015 CLEARPOINT *coviD impact on Elective 801 Procedures 682* 2016 2017 2018 2019 2020 aus 2021 Biologics and Drug Delivery m= Capital and Software Functional Neurosurgery $3.4 2014 «©2015 = 2016 $5.2 2017 $16.3 $11.2 $5.4 Bosra El sos $8.4 201
Slide 12: ClearPoint Neuro Market Opportunity — United States
Pillar 4: Global Expansion ClearPoint Neuro Market Opportunity — United States 2X U.S. Revenue ~$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications* feast 7 7 a Pillar 1: C Indication ) (Patient Population )( Annual Incidence ) Drug/Cell oe Gaia) Incremental Revenue from Ann
Slide 13: Market Opportunity Citations & Footnotes
ClearPoint Neuro Market Opportunity — United States Citations & Footnotes 1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older 2. Neurona Therapeutics. (2021 N
Slide 14: Innovation Pipeline
Innovation Pipeline ClearPoint Neuro is Dedicated to Innovation in the Neuro Space Expected 2022 First-Clinical Use* ClearPoint Maestro™ Brain Model Revolution™ Robotic-Assisted Navigation Closed Loop Robotic-Assisted Brain Computer Navigation Interface Navigation ClearPoint Neuro Navigation Maestro
Slide 15: New Global Showcase Site
New Global Showcase Site ClearPoint Global Training & Innovation Center — Solana Beach, CA ¢ Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback * Showcase new technologies to Pharmaceutical and BCI partners Home for Clinical Spec
Slide 16: Pillar Growth Strategy by 2025
4 Pillar Growth Strategy by 2025 Target Indications of > 1,000,000 Patients Diagnosed Each Year Potential Total Addressable Market for CLPT of $12B+ 2022 es CLEARPOINT ACHIEVE GLOBAL SCALE Expand Global Footprint to 100 Centers Open WW Training / Remote Support Facility Launch Robotic Platform into
Slide 17: CLPT Capabilities Executive Summary
CLPT Capabilities Executive Summary = Unique platform technology Fad enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Pipeline of new revenue streams ae from product improvements, biologic and drug delivery partnerships and services, stan
Slide 18: Nasdaq
2 ie Nasdaq Composite Nasdaq100 so at 99 + 0.18% COMP 40.20% 40.29% DJI v0. ae 0.18% +19.21 9,731.18 +2788 9,623.58 c °. amazon” prt ol Bee 0.74% wa ee00 aS Rid COMCAST pepsico matchaioup ER guesa *0,04% Pep *0.36% rcH *1,72% SBUX 10.72% AMZN a © 2022 CLEARPOINT NEURO -\ A Sk =
Slide 19: ClearPoint Neuro
CLEARPOINT NEURO S A, Wy emit = AZ CL pS \\ ZX" Si] NSE RA
ClearPoint Neuro — Investor Presentation (February 2022) on 6ix